Nineteen new halogenated diarylpyridinamine (DAPA) analogues modified at the phenoxy C-ring were synthesized and evaluated for anti-HIV activity and certain drug-like properties. Ten compounds showed high anti-HIV activity (EC50<10 nm). In particular, (E)-6-(2 ''-bromo-4 ''-cyanovinyl-6 ''-methoxy) phenoxy-N-2-(4'-cyanophenyl) pyridin-2,3-diamine (8c) displayed low-nanomolar antiviral potency (3-7 nm) against wild-type and drug-resistant viral strains bearing the E138K or K101E mutations, which are associated with resistance to rilvipirine (1b). Compound 8c exhibited much lower resistance fold changes (RFC: 1.1-2.1) than 1b (RFC: 11.8-13.0). Compound 8c also exhibited better metabolic stability (in vitro half-life) than 1b in human liver microsomes, possessed low lipophilicity (clogD: 3.29; measured logP: 3.31), and had desirable lipophilic efficiency indices (LE>0.3, LLE>5, LELP<10). With balanced potency and drug-like properties, 8c merits further development as an anti-HIV drug candidate.